Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy

This study compares two treatments for primary membranous nephropathy (PMN) — a kidney disease that causes protein to leak into urine: rituximab combined with corticosteroids versus rituximab alone. The goal is to find the safest, most effective approach with fewer side effects. You may be eligible if... - You are between 18 and 75 years old - You have a confirmed diagnosis of primary membranous nephropathy via kidney biopsy - You have significant protein in your urine (24-hour urine protein ≥ 3.5g) despite at least 3 months of ACE inhibitor or ARB treatment - Your kidney filtration rate (eGFR) is at least 30 mL/min/1.73m² - You are using contraception if female and not post-menopausal You may NOT be eligible if... - You have diabetes with kidney complications - You have secondary membranous nephropathy (caused by hepatitis, lupus, drugs, or cancer) - You have previously been treated with rituximab, steroids, or certain immunosuppressants - You have an active infection (hepatitis B or C, tuberculosis, HIV) - You are pregnant, breastfeeding, or planning pregnancy in the next 24 months - You have severely low blood counts or significantly elevated liver enzymes Talk to your doctor to see if this trial is right for you.